FDA Grants 37 Breakthrough Designations in 2013
Since the FDA’s breakthrough therapy designation (BTD) was put into effect in July of 2012, pharma and biotech companies have certainly taken note, according to the new report, “Breakthrough Therapy Designation: A Breakthrough Year for Unmet Diseases,” from EP Vantage, the editorial arm of Evaluate.
The FDA data indicate that no fewer than 141 BTDs have been applied for, of which 37 have been granted. Thus far, three breakthrough-designated products have received US approval: Roche's Gazyva, J&J/Pharmacyclics' Imbruvica and Gilead's Sovaldi.
The jury is still out, however, on what it actually means in practice for a project to be designated a breakthrough therapy, and attempts to highlight evidence of shortened approval times for BTD products look premature. The new EP Vantage report takes a deeper look at this new designation and how small and large pharma are looking to reap the benefits the designation is touted to provide.
“Although many companies have been quick to play up the potential advantages of a breakthrough designation, the fact is that no one actually knows what these are in practice,” said Jacob Plieth, report author and EP Vantage senior editorial analyst. “Little can be gleaned from the three products to have already received US approval, and many uncertainties still abound.”
A list of the 30 disclosed breakthrough projects reveals that the vast majority have favoured big pharma and big biotech — despite the fact that the FDA’s promise to provide assistance on clinical trial design and guidance on development was aimed at small, cash-strapped biotechs, notes Plieth. According to the report, the hope is that this trend will shift as the programme matures.
The report, based on market intelligence and analysis from EvaluatePharma can be downloaded here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance